MA54522B1 - Macitentan pour le traitement de l'hypertension artérielle pulmonaire - Google Patents
Macitentan pour le traitement de l'hypertension artérielle pulmonaireInfo
- Publication number
- MA54522B1 MA54522B1 MA54522A MA54522A MA54522B1 MA 54522 B1 MA54522 B1 MA 54522B1 MA 54522 A MA54522 A MA 54522A MA 54522 A MA54522 A MA 54522A MA 54522 B1 MA54522 B1 MA 54522B1
- Authority
- MA
- Morocco
- Prior art keywords
- pah
- treatment
- aprocitentan
- macitentan
- prevention
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title abstract 9
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 abstract 6
- DKULOVKANLVDEA-UHFFFAOYSA-N ACT-132577 Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)N)=NC=NC=1OCCOC1=NC=C(Br)C=N1 DKULOVKANLVDEA-UHFFFAOYSA-N 0.000 abstract 5
- 229940070148 aprocitentan Drugs 0.000 abstract 5
- 229960001039 macitentan Drugs 0.000 abstract 5
- 230000002265 prevention Effects 0.000 abstract 4
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 229940127314 Prostacyclin Receptor Agonists Drugs 0.000 abstract 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 abstract 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003119 guanylate cyclase activator Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000877 morphologic effect Effects 0.000 abstract 1
- 150000003815 prostacyclins Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des doses élevées de macitentan, c'est-à-dire de l'acide propylsulfamique [5-(4-bromo-phényl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-éthoxy]-pyrimidin-4-yl]-amide ou des sels, solvates, hydrates ou formes morphologiques pharmaceutiquement acceptables de celui-ci, ou d'aprocitentan, destinés à être utilisés dans le traitement et/ou la prévention de l'hypertension artérielle pulmonaire (HTAP). De plus, la présente invention concerne l'utilisation de doses élevées de macitentan, ou d'aprocitentan, pour la fabrication d'un médicament destiné au traitement et/ou à la prévention de l'HTAP, ainsi qu'une méthode de traitement et/ou de prévention de l'HTAP comprenant des doses élevées de macitentan ou d'aprocitentan. L'invention concerne en outre un schéma posologique pour le traitement et/ou la prévention de l'HTAP ainsi qu'une combinaison de macitentan ou d'aprocitentan avec un ou plusieurs inhibiteurs de la phosphodiestérase de type 5 (PDE5), des analogues de la prostacycline, des agonistes du récepteur de la prostacycline ou des stimulateurs de la guanylate cyclase soluble. L'HTAP est de préférence une HTAP légère ou modérée. De plus, l'invention concerne une composition pharmaceutique pour le traitement de l'HTAP comprenant une dose élevée de macitentan ou d'aprocitentan.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018086724 | 2018-12-21 | ||
| EP2019051830 | 2019-01-25 | ||
| EP2019060151 | 2019-04-18 | ||
| EP2019066494 | 2019-06-21 | ||
| EP2019067186 | 2019-06-27 | ||
| EP19832954.2A EP3897646B1 (fr) | 2018-12-21 | 2019-12-20 | Macitentan pour le traitement de l'hypertension artérielle pulmonaire |
| PCT/EP2019/086754 WO2020128017A1 (fr) | 2018-12-21 | 2019-12-20 | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54522A MA54522A (fr) | 2022-03-23 |
| MA54522B1 true MA54522B1 (fr) | 2024-07-31 |
Family
ID=69147670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54522A MA54522B1 (fr) | 2018-12-21 | 2019-12-20 | Macitentan pour le traitement de l'hypertension artérielle pulmonaire |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11234980B2 (fr) |
| EP (1) | EP3897646B1 (fr) |
| JP (2) | JP7871054B2 (fr) |
| KR (1) | KR20210109558A (fr) |
| CN (1) | CN113194953A (fr) |
| AU (1) | AU2019410727B2 (fr) |
| BR (1) | BR112021011999A2 (fr) |
| CA (1) | CA3123990A1 (fr) |
| CL (1) | CL2021001636A1 (fr) |
| CO (1) | CO2021007186A2 (fr) |
| DK (1) | DK3897646T3 (fr) |
| ES (1) | ES2983314T3 (fr) |
| FI (1) | FI3897646T3 (fr) |
| HR (1) | HRP20240875T1 (fr) |
| HU (1) | HUE067126T2 (fr) |
| IL (1) | IL284136A (fr) |
| JO (1) | JOP20210153B1 (fr) |
| LT (1) | LT3897646T (fr) |
| MA (1) | MA54522B1 (fr) |
| MX (1) | MX2021007455A (fr) |
| PH (1) | PH12021551371A1 (fr) |
| PL (1) | PL3897646T3 (fr) |
| PT (1) | PT3897646T (fr) |
| RS (1) | RS65689B1 (fr) |
| SG (1) | SG11202105098VA (fr) |
| SI (1) | SI3897646T1 (fr) |
| SM (1) | SMT202400274T1 (fr) |
| TW (1) | TWI841649B (fr) |
| WO (1) | WO2020128017A1 (fr) |
| ZA (1) | ZA202105111B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA126122C2 (uk) | 2017-02-27 | 2022-08-17 | Ідорсія Фармасьютікалз Лтд | Комбінації похідної 4-піримідинсульфаміду з активними інгредієнтами для лікування захворювань, пов'язаних з ендотеліном |
| WO2020074957A1 (fr) * | 2018-10-12 | 2020-04-16 | Sanotize Research And Development Corp. | Compositions à dégagement de gaz et systèmes de récipient et de distribution |
| EP3897646B1 (fr) | 2018-12-21 | 2024-05-22 | Actelion Pharmaceuticals Ltd | Macitentan pour le traitement de l'hypertension artérielle pulmonaire |
| TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| IL293271A (en) * | 2019-11-29 | 2022-07-01 | Actelion Pharmaceuticals Ltd | Methods for treating pulmonary artery hypertension |
| WO2022180194A1 (fr) * | 2021-02-26 | 2022-09-01 | Actelion Pharmaceuticals Ltd | Procédés de traitement de l'hypertension pulmonaire chez des patients ayant une implantation de dispositif d'assistance ventriculaire gauche |
| WO2026089673A1 (fr) * | 2024-10-24 | 2026-04-30 | Humanis Sağlik A.Ş. | Compositions pour l'hypertension artérielle pulmonaire |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1693372A1 (fr) | 2000-12-18 | 2006-08-23 | Actelion Pharmaceuticals Ltd. | Nouveaux sulfamides et leur utilisation comme antagoniste du récepteur d'endotheline |
| ES2393117T3 (es) | 2005-09-12 | 2012-12-18 | Actelion Pharmaceuticals Ltd. | Composición farmacéutica estable que comprende una pirimidina-sulfamida |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| MX350011B (es) | 2008-08-13 | 2017-08-22 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas que contienen macitentan. |
| IL266518B2 (en) | 2016-11-10 | 2026-05-01 | Arena Pharm Inc | Methods for treating pulmonary hypertension with combinations of relinfag and other substances |
| WO2018153925A1 (fr) * | 2017-02-22 | 2018-08-30 | Amneal Pharmaceuticals Company Gmbh | Compositions pharmaceutiques stables comprenant du macitentan |
| UA126122C2 (uk) | 2017-02-27 | 2022-08-17 | Ідорсія Фармасьютікалз Лтд | Комбінації похідної 4-піримідинсульфаміду з активними інгредієнтами для лікування захворювань, пов'язаних з ендотеліном |
| EP3897646B1 (fr) | 2018-12-21 | 2024-05-22 | Actelion Pharmaceuticals Ltd | Macitentan pour le traitement de l'hypertension artérielle pulmonaire |
| TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| TW202103703A (zh) | 2019-04-05 | 2021-02-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療門脈肺高血壓之方法 |
| JOP20220126A1 (ar) | 2019-11-26 | 2023-01-30 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية لعلاج أمراض الأوعية الدموية الرئوية و/أو خلل وظيفي في القلب لمرضى فونتان المُخفّف |
-
2019
- 2019-12-20 EP EP19832954.2A patent/EP3897646B1/fr active Active
- 2019-12-20 HU HUE19832954A patent/HUE067126T2/hu unknown
- 2019-12-20 BR BR112021011999-0A patent/BR112021011999A2/pt unknown
- 2019-12-20 ES ES19832954T patent/ES2983314T3/es active Active
- 2019-12-20 MA MA54522A patent/MA54522B1/fr unknown
- 2019-12-20 WO PCT/EP2019/086754 patent/WO2020128017A1/fr not_active Ceased
- 2019-12-20 KR KR1020217022508A patent/KR20210109558A/ko not_active Ceased
- 2019-12-20 SG SG11202105098VA patent/SG11202105098VA/en unknown
- 2019-12-20 AU AU2019410727A patent/AU2019410727B2/en active Active
- 2019-12-20 TW TW108146917A patent/TWI841649B/zh active
- 2019-12-20 HR HRP20240875TT patent/HRP20240875T1/hr unknown
- 2019-12-20 SI SI201930781T patent/SI3897646T1/sl unknown
- 2019-12-20 DK DK19832954.2T patent/DK3897646T3/da active
- 2019-12-20 LT LTEPPCT/EP2019/086754T patent/LT3897646T/lt unknown
- 2019-12-20 CA CA3123990A patent/CA3123990A1/fr active Pending
- 2019-12-20 MX MX2021007455A patent/MX2021007455A/es unknown
- 2019-12-20 PL PL19832954.2T patent/PL3897646T3/pl unknown
- 2019-12-20 JP JP2021533836A patent/JP7871054B2/ja active Active
- 2019-12-20 CN CN201980084868.5A patent/CN113194953A/zh active Pending
- 2019-12-20 SM SM20240274T patent/SMT202400274T1/it unknown
- 2019-12-20 FI FIEP19832954.2T patent/FI3897646T3/fi active
- 2019-12-20 RS RS20240742A patent/RS65689B1/sr unknown
- 2019-12-20 PT PT198329542T patent/PT3897646T/pt unknown
-
2021
- 2021-03-02 US US17/189,881 patent/US11234980B2/en active Active
- 2021-05-31 CO CONC2021/0007186A patent/CO2021007186A2/es unknown
- 2021-06-10 PH PH12021551371A patent/PH12021551371A1/en unknown
- 2021-06-16 JO JOJO/P/2021/0153A patent/JOP20210153B1/ar active
- 2021-06-17 IL IL284136A patent/IL284136A/en unknown
- 2021-06-18 CL CL2021001636A patent/CL2021001636A1/es unknown
- 2021-07-20 ZA ZA2021/05111A patent/ZA202105111B/en unknown
- 2021-10-29 US US17/515,132 patent/US11464777B2/en active Active
-
2022
- 2022-09-27 US US17/953,530 patent/US20230020241A1/en not_active Abandoned
-
2024
- 2024-05-08 JP JP2024075949A patent/JP2024105450A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551371A1 (en) | Pharmaceutical composition for the treatment of pulmonary arterial hypertension | |
| PH12021551728A1 (en) | Pharmaceutical composition for the treatment of chronic thromboembolic pulmonary hypertension | |
| EP4643882A3 (fr) | Inhibiteurs de capsides pour la prévention du vih | |
| ZA202007681B (en) | Pharmaceutical combination, composition and combination formulation comprising glucokinase activator and dpp-iv inhibitor, and preparation method and use thereof | |
| MX2025001619A (es) | Inhibidor de pde4b y uso del mismo | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| PH12019502052A1 (en) | Hepatitis b virus surface antigen inhibitor | |
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| MX2019009841A (es) | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. | |
| EA201071094A1 (ru) | Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| PH12022551359A1 (en) | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | |
| MX2023003576A (es) | Compuesto como inhibidor de la akt cinasa. | |
| MY207397A (en) | Pharmaceutical composition comprising sglt-2 inhibitor and dpp-iv inhibitor | |
| EP4599894A3 (fr) | Procédés de traitement de l'urticaire chronique spontanée à l'aide d'un inhibiteur de tyrosine kinase de bruton s | |
| MY209603A (en) | Hydroxypyridoxazepines as nrf2 activators | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| WO2018027084A3 (fr) | Combinaison d'antagonistes de récepteur du glucagon et d'inhibiteurs de la voie pi3k pour le traitement du cancer | |
| MX2023013225A (es) | Inhibidores de la cinasa 4 similar a polo. | |
| HK1243704A1 (zh) | 用於在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案 | |
| PH12022551295A1 (en) | Pharmaceutical composition for the treatment of pulmonary vascular disease and/or cardiac dysfunction in fontan-palliated patients | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. | |
| EA202192062A1 (ru) | Фармацевтическая композиция, содержащая мацитентан, для лечения хронической тромбоэмболической легочной гипертензии | |
| HK1252549A1 (zh) | 控释tozadenant制剂 | |
| AR115293A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| EA202191733A1 (ru) | Фармацевтическая композиция для лечения легочной артериальной гипертензии |